Bioinformatics analysis of TCGA data revealed that the expression levels of a panel of neuronal genes in GBM were significantly lower than those in non-tumor tissues (Supplementary Fig. S8G), and patients with high NEUROD1 or MAP2 expression had a better outcome (Supplementary Fig. S8H). This evidence concerns the gene NEUROD1 and glioblastoma.